



- (51) **International Patent Classification:**
A61P 35/00 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/US2021/017268
- (22) **International Filing Date:**
09 February 2021 (09.02.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/976,869 14 February 2020 (14.02.2020) US
63/130,157 23 December 2020 (23.12.2020) US
- (71) **Applicant: JOUNCE THERAPEUTICS, INC.** [US/US];
780 Memorial Drive, Cambridge, Massachusetts 02139 (US).
- (72) **Inventors: MCGRATH, Lara, Lewis;** c/o JOUNCE THERAPEUTICS, INC., 780 Memorial Drive, Cambridge, Massachusetts 02139 (US). **DÉPIS, Fabien;** c/o JOUNCE THERAPEUTICS, INC., 780 Memorial Drive, Cambridge, Massachusetts 02139 (US). **HU, Changyun;** c/o JOUNCE THERAPEUTICS, INC., 780 Memorial Drive, Cambridge,


Massachusetts 02139 (US). **PRESTA, Leonard, G.;** c/o JOUNCE THERAPEUTICS, INC., 780 Memorial Drive, Cambridge, Massachusetts 02139 (US). **BUGGÉ, Joshua, Adam;** c/o JOUNCE THERAPEUTICS, INC., 780 Memorial Drive, Cambridge, Massachusetts 02139 (US).

- (74) **Agent: SCHMIDT, Jeffrey et al.;** Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

- (54) **Title: ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF**



- (57) **Abstract:** Provided herein are various embodiments relating to antibodies and fusion proteins and uses thereof. Some of the embodiments include antibodies that bind CCR8. Some of the embodiments include fusion proteins that bind CCR8. Such antibodies and fusion proteins can be used in methods to treat, for example, cancer.

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*